Fujifilm may restart scientific trial of Avigan for COVID19

Fujifilm Holdings is considering restarting a clinical test in Japan for the anti-viral drug Avigan in treating COVID-19 patients, company options said Sunday, following the government held off approval of the drug overdue last year.

Particulars, including when the trial would start, methods to be taken and target patients have yet to become determined, the options said. Approval associated with Avigan could increase treatment options in the country past the two at present available.

Japan authorities has approved typically the anti-viral drug remdesivir, developed by US firm Gilead Savoir, and the steroid dexamethasone for COVID-19 treatment.

The use of Avigan could possibly be expanded if the government greenlights it as a COVID-19 therapeutic agent as well. indopos online offer Avigan to coronavirus sufferers who wish to be able to have it implemented to them as an "observational research. "

Keep away from, the health ministry panel judged that it is challenging to reach the conclusion on typically the effectiveness of Avigan based on the results of clinical testing. But a ministry recognized said the decision performed not entirely eliminate the effectiveness regarding the drug.

Drugmaker Fujifilm Toyama Substance, a unit regarding Fujifilm, filed with regard to COVID-19 approval in October.



Avigan, also known as favipiravir, has already obtained approval as a good influenza drug. Nevertheless some medical experts have opposed the use of Avigan for the therapy of coronavirus.

Feasible side effects include decreased liver function, but Fujifilm stated no new security concerns were recognized. Pregnant women cannot use the drug since some animal studies have pointed to be able to possible fetal abnormalities.